The organization
identified adverse effects of the interaction of HCV medicine and the pill
hormone (*)
 |
| The warning is valid for all women who undergo hepatitis C treatment |
The National Heath Surveillance
Agency (ANVISA), published on August 17, a health warning
addressed to women who takes the medicine Viekira Pak in their treatment against
hepatitis C. According to the Government Agency, women who undergo HCV
treatment taking this specific drug are forbidden to take oral contraceptive containing
ethynil estradiol – semisynthetic hormone.
According to ANVISA, there
are risks of side effects at the drugs interaction. The agency recommend the
patients to see a doctor for guidance about going off the pill or switching the
contraceptive method and also if they feel unusual tiredness and weakness, lack
of appetite, nausea and vomiting or light-colored stools during the treatment with
Viekira Pak.
According to ANVISA, the use
of contraceptives containing ethynil estradiol should be discontinued two weeks
prior to start Viekira Pak therapy. During the treatment, patients may use different
formulation of oral contraceptive or change the medicine to a non- hormonal contraceptive
method. After ending the treatment, the ethynil estradiol contraceptive treatment
can be restarted two weeks after ending Viekira Pack treatment.
Since August 2016, Anvisa, in
association with the Ministry of Health, has been monitored the adverse effects
for the use of new drugs that were newly introduced, in June 2015, into SUS (Unified
Heath System) for the treatment of hepatitis C.
(*) By Júlia Marques, O Estado de S. Paulo, August 18, 2017
Para ler a reportagem em português, acesse Anvisa faz alerta para uso de anticoncepcional por mulheres com hepatite C.
Nenhum comentário:
Postar um comentário